Celldex Therapeutics halted development of its experimental eczema treatment on Thursday after the drug missed primary and secondary goals in a mid-stage trial. Shares fell 3.2% in extended trading following the announcement. The trial failure forces the drug developer to abandon its atopic dermatitis program entirely.
Celldex ends eczema drug trial
Celldex Therapeutics has halted development of its experimental eczema treatment after it failed to meet main goals in a mid-stage study. The drug did not significantly reduce itching compared to placebo. However, the company will continue other trials.
Insights:





